(IN BRIEF) Researchers at the Institute of Cancer Research have demonstrated how immuno-PET imaging can be used to track the immune system’s response to oncolytic virotherapy in real time. Using a modified virus known as RP1 in preclinical models of … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Cancer Immunotherapy, Cancer Research UK, cancer treatment innovation, Chellaram Foundation, Gabriela Kramer Marek, head and neck cancer, ICR London, ICR research demonstrates potential of advanced imaging to guide personalised cancer treatment strategies, immune response, immuno PET, Immuno PET technology offers new insights into timing and effectiveness of cancer immunotherapy combinations, Institute of Cancer Research, Journal of Nuclear Medicine, Julia Höbart, molecular imaging, oncology research, oncolytic virotherapy, Oracle Cancer Trust, PD-L1, RP1 virus
(IN BRIEF) A new study led by researchers at The Institute of Cancer Research, London, has identified a promising new combination therapy for pancreatic cancer that could transform future treatment. The dual approach — combining boiling histotripsy and oncolytic reovirus … Read the full press release
Posted in Business, Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged boiling histotripsy, cancer research, cancer treatment innovation, Gail ter Haar, ICR, ICR study identifies new immune-based combination strategy to improve pancreatic cancer treatment outcomes, immune response, immunotherapy, Institute of Cancer Research, macrophages, neutrophils, oncolytic reovirus, pancreatic cancer, Pancreatic cancer study from ICR highlights new dual treatment approach and reveals key immune cell insights, Pancreatic Cancer UK, Petros Mouratidis, Pharmaceutics, preclinical study, The Institute of Cancer Research identifies promising dual treatment strategy for pancreatic cancer, tumour microenvironment, ultrasound therapy, viral immunotherapy
(IN BRIEF) AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application for Enhertu plus pertuzumab has been accepted for Priority Review by the FDA for the first-line treatment of HER2-positive metastatic breast cancer. The application is supported by data from the … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged ADC, antibody-drug conjugate, AstraZeneca, breakthrough therapy designation, cancer treatment innovation, Daiichi Sankyo, DESTINY-Breast09, Enhertu, Enhertu plus pertuzumab moves closer to first-line approval in HER2-positive metastatic breast cancer after FDA Priority Review acceptance, FDA, FDA grants Priority Review to Enhertu plus pertuzumab for 1st-line HER2-positive metastatic breast cancer following DESTINY-Breast09 success, HER2-positive breast cancer, Ken Takeshita, metastatic breast cancer, oncology, pertuzumab, Priority Review, progression-free survival, Real-Time Oncology Review, Susan Galbraith, THP regimen, trastuzumab deruxtecan
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?